SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Morgan Stanley Smith Barney LLC filed a Rule 144 notice relating to 608 Restricted Stock Units dated 03/18/2026 to be sold. The entry lists the securities as Common and identifies the issuer role as Issuer.
The filing also shows recent 10b5-1 sales by Philippe Menu, including transactions of 5,000 shares on 03/12/2026 for $22,592.50 and 608 shares on 02/19/2026 for $2,932.38.
Manuela Valente reported sales of Common Stock under Rule 144 via pre-arranged 10b5-1 transactions. The filing lists multiple dispositions: 01/05/2026 2,085 shares, 01/06/2026 636 shares, 01/20/2026 380 shares, and 02/19/2026 380 shares. The trades show an executing broker Morgan Stanley Smith Barney LLC and reference Restricted Stock Units as the security type.
JURGI CAMBLONG reported multiple 10b5-1 sales of Common stock executed through Morgan Stanley Smith Barney LLC as broker. The excerpt lists individual sales from 12/29/2025 through 03/16/2026 with per-trade share counts and proceeds.
Examples shown include sales of 95,488 shares on 01/09/2026 and 37,299 shares on 01/22/2026, executed under a 10b5-1 plan. The filing lists Restricted Stock Units and trade dates; cash-flow treatment is not stated in the provided excerpt.
SOPHiA GENETICS SA director Tomer Berkovitz filed an initial Form 3, which is a baseline report of insider status and equity interests. This filing does not list any insider transactions or derivative positions in the provided data, and serves as an initial ownership disclosure for this director.
SOPHiA GENETICS SA director Kathy L. Hibbs filed an initial ownership report showing holdings in ordinary shares and share options. She reports 97,276 ordinary shares, including 33,784 shares underlying restricted share units that vest in full at the company’s next annual shareholder meeting, subject to continued service. She also holds fully vested and exercisable options over 140,000 ordinary shares at an exercise price of 5.9800 per share expiring on March 26, 2031, and options over 49,751 ordinary shares at 3.0400 per share expiring on June 18, 2035.
SOPHiA GENETICS SA director Jean-Michel Cossery filed an initial ownership report showing his equity stake in the company. He directly holds 186,488 ordinary shares, including 33,784 shares to be delivered from a restricted share unit award that vests at the next annual shareholder meeting, subject to continued service.
He also holds share options over 59,880 ordinary shares at an exercise price of 2.5300, expiring on October 2, 2033, which vest in thirds annually on the date of the company’s annual shareholder meeting. A further option covers 49,751 ordinary shares at an exercise price of 3.0400, expiring on June 18, 2035, vesting 100% at the next scheduled annual shareholder meeting, also subject to continued service.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported his initial ownership on a Form 3. He directly holds 92,419 ordinary shares, including 30,405 shares issuable upon settlement of five restricted stock unit grants that vest over time with continued service.
He also holds several vested and unvested share options to buy ordinary shares at exercise prices ranging from 3.29 to 18.00, with expiration dates from 2029 through 2035. These option and RSU awards reflect his equity-based compensation and align part of his pay with the company’s share performance.
SOPHiA GENETICS SA filed an initial ownership report for Chief Legal Officer Daan Van Well, outlining his equity position in the company. He directly holds 261,922 ordinary shares, which includes 97,620 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time based on continued service. He also holds several option awards to buy ordinary shares, with exercise prices ranging from $3.29 to $18.00 per share and expiration dates between 2029 and 2035, providing long-term equity exposure but reflecting holdings rather than new market transactions.
SOPHiA GENETICS SA director Didier Hirsch filed an initial ownership report. He holds 220,496 ordinary shares, including 33,784 shares to be delivered upon settlement of a restricted share unit award that vests in full at the company’s next annual shareholders’ meeting, subject to continued service.
He also holds fully vested and exercisable share options over 140,000 ordinary shares at an exercise price of 4.2100 per share expiring on June 25, 2030, and options over 49,751 ordinary shares at 3.0400 per share expiring on June 18, 2035.
SOPHiA GENETICS SA director Vincent Ossipow filed an initial ownership report showing 503,136 ordinary shares held directly, including 33,784 shares to be delivered under a restricted share unit award that vests at the next annual shareholder meeting.
He also holds fully vested, exercisable share options over 60,000 ordinary shares at an exercise price of $6.31 expiring on January 28, 2031, and options over 49,751 ordinary shares at $3.04 expiring on June 18, 2035.